Makoto KAWATANI


Makotoo KAWATANI
(Ph.D, Senior Research Scientist)
INTEREST OF MY RESEARCH
Microorganisms often produce useful compounds for us. I have screened such compounds, especially anticancer compounds, and have studied their mode of action. I want to contribute to development of new drugs through chemical biology research.
EDUCATION
1994-1998
Faculty of Science and Technology, Keio University
2001-2003
JSPS research fellowships for young scientists
1998-2003
Graduate School of Science and Technology, Keio University
DEGREES
B.Sc. (1998)
Keio University
Dr. Science (2003)
Keio University
APPOINTMENTS
2003-2004
Postdoctoral Researcher, Antibiotics Laboratory, RIKEN
2004-2007
Special Postdoctoral Researcher, Antibiotics Laboratory, RIKEN
2007-2009
Postdoctoral Researcher, Antibiotics Laboratory, RIKEN
2009-2012
Research Scientist, Antibiotics Laboratory, RIKEN
2012-2015
Senior Research Scientist, Chemical Biology Core Facility, RIKEN ASI
2015.Apr.-
Senior Research Scientist, Chemical Biology Research Group, RIKEN CSRS
AWARDS
  • The Excellent Paper Award Published in Bioscience, Biotechnology, & Biochemistry (2007)
  • Best Presentation Award, 2007 Annual Meeting of the Japanese Association for Molecular Target Therapy of Cancer (2007)
  • Research Incentive Award of RIKEN (2009)
  • The Excellent Paper Award Published in Bioscience, Biotechnology, & Biochemistry (2009)
  • The Research Incentive Award of the Japanese Association for Molecular Target Therapy of Cancer (2009)
  • Japanese Cancer Association Incitement Award (2012)
ACADEMIC ACTIVITIES
  • Japanese Cancer Association
  • The Japanese Association for Molecular Target Therapy of Cancer (Councilor)
  • Japan Society for Bioscience, Biotechnology, and Agrochemistry
  • Japanese Society for Chemical Biology
  • Oncology Research (Editorial Board Member)
MY HOBBY
Football, Badminton
LIST OF SELECTED PUBLICATIONS
  1. Kawamura T.*, Kawatani M.*, Muroi M., Kondoh Y., Futamura Y., Aono H., Tanaka M., Honda K., and Osada H. Proteomic profiling of small-molecule inhibitors reveals dispensability of MTH1 for cancer cell survival. Sci. Rep. 6, 26521 (2016) *, equal contribution
  2. Kawatani M., Fukushima Y., Kondoh Y., Honda K., Sekine T., Yamaguchi Y., Taniguchi N., and Osada H. Identification of matrix metalloproteinase inhibitors by chemical arrays. Biosci. Biotechnol. Biochem. 79, 1597-1602 (2015)
  3. Kawatani M., and Osada H. Affinity-based target identification for bioactive small molecules. MedChemComm 5, 277-287 (2014) Review Article
  4. Futamura Y., Kawatani M., Muroi M., Aono H., Nogawa T., and Osada H. Molecular target identification of a novel fungal metabolite, pyrrolizilactone, by phenotypic profiling systems. Chembiochem 14, 2456-2463 (2013)
  5. Futamura Y.*, Kawatani M.*, Kazami S., Tanaka K., Muroi M., Shimizu T., Tomita K., Watanabe N., and Osada H. Morphobase, an encyclopedic cell morphology database, and its use for drug target identification. Chem. Biol. 19, 1620-1630 (2012) *, equal contribution
  6. Kawatani M., Takayama H., Muroi M., Kimura S., Maekawa T., and Osada H. Identification of a small-molecule inhibitor of DNA topoisomerase II by proteomic profiling. Chem. Biol. 18, 743-751 (2011)
  7. Kawatani M., and Osada H. Osteoclast-targeting small molecules for the treatment of neoplastic bone metastases. Cancer Sci. 100, 1999-2005 (2009) Review Article
  8. Kawatani M., Okumura H., Honda K., Kanoh N., Muroi M., Dohmae N., Takami M., Kitagawa M., Futamura Y., Imoto M., and Osada H. The identification of an osteoclastogenesis inhibitor through the inhibition of glyoxalase I. Proc. Natl. Acad. Sci. USA 105, 11691-11696 (2008)
  9. Woo J.-T.*, Kawatani M.*, Kato M., Shinki T., Yonezawa T., Kanoh N., Nakagawa H., Takami M., Lee K. H., Stern P. H., Nagai K., and Osada H. Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts. Proc. Natl. Acad. Sci. USA 103, 4729-4734 (2006) *, equal contribution
  10. Kawatani M., and Imoto M. Deletion of the BH1 domain of Bcl-2 accelerates apoptosis by acting in a dominant negative fashion. J. Biol. Chem. 278, 19732-19742 (2003)

Additional information